Key Highlights
- Michael Gutch, Ph.D., joins as Chief Operating Officer
- Over two decades of life sciences industry experience
- Led finance and business development at Noema Pharma AG
- Extensive background in biotech and pharmaceutical leadership
Source: Business Wire
Notable Quotes
- “Mike has a remarkable wealth of experience across the life sciences ecosystem, giving him deep pharma and biotech operations, finance, and business development expertise that spans development and strategy, complex financings and transactions, and investor relations,” – Victoria Richon, Ph.D., CEO at Entact Bio
- “I am thrilled to join the Entact team at this important juncture in its evolution. It is an incredible opportunity to join a company pioneering an entirely new small-molecule modality with vast potential to treat historically undruggable diseases.” – Michael Gutch, Ph.D., Chief Operating Officer at Entact Bio
SoHC's Take
The appointment of Dr. Michael Gutch as Chief Operating Officer at Entact Bio marks a significant strategic move for the company. With his extensive experience in the life sciences sector, particularly in biotech and pharmaceutical operations, finance, and business development, Dr. Gutch is well-positioned to drive Entact Bio’s growth. His leadership will be instrumental in advancing the company’s proprietary Encompass™ platform and ENTAC™ medicines towards clinical application. This move underscores Entact Bio’s commitment to pioneering innovative therapeutic solutions for previously untreatable diseases, potentially revolutionizing the field of precision medicine.
Related

Entact Bio Appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer
Key Highlights Entact Bio appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer.Dr. Tommasi brings 30 years of drug discovery leadership across multiple therapeutic areas.Tommasi previously served at Dunad Therapeutics and Entasis Therapeutics, driving successful clinical outcomes.Entact Bio focuses on precision medicines that enhance beneficial protein function via the Encompass™ platform.Source: Business Wire Notable Quotes “We’re thrilled to welcome…

Dren Bio Announces Strategic Collaboration with Novartis Pharma AG
Key Highlights Dren Bio partners with Novartis for bispecific antibody development.$150 million upfront consideration, including $25 million equity investment.Potential additional payments up to $2.85 billion.Focus on cancer therapy using Dren Bio's proprietary platform.Source: Business Wire Notable Quotes "Our agreement with Dren Bio is a promising opportunity to discover novel bispecific…

Nura Bio Secures $140M in Series A Financing and Appoints Shilpa Sambashivan, Ph.D., as CEO
Key Highlights Nura Bio closes $140M Series A financing to support clinical development.Shilpa Sambashivan, Ph.D., appointed as CEO following Phase 1 success of NB-4746.NB-4746 is a brain-penetrant SARM1 inhibitor with potential neuroprotective benefits.Phase 1 trial results show NB-4746 was well-tolerated and achieved target plasma exposure.Source: Business Wire Notable Quotes “Under Shilpa’s leadership, Nura Bio has…